Newsletter · · Ashutosh Agarwal

GLP-1 Bridge Program Goes Live as IRA Rebate Collapse Squeezes PBMs and Hospitals - Healthcare Policy: Drug Pricing, IRA & Managed Care - Week of June 27, 2026

Healthcare policy newsletter for the week of June 27, 2026. The IRA is collapsing the rebate spread that feeds PBMs and 340B hospitals from the inside, Medicare's GLP-1 Bridge Program launches July 1 at $50/month, and Medicaid work requirements plus the ACA subsidy cliff set up a 2027-2028 coverage reckoning for managed care.

Healthcare Policy: Drug Pricing, IRA & Managed Care

Week of June 27, 2026: GLP-1 Bridge Program Goes Live as IRA Rebate Collapse Squeezes PBMs and Hospitals

Weekly recap, week ending June 27, 2026

Intro

Few new laws passed this week, but the tape was a master class in second-order mechanics: how the Inflation Reduction Act is dismantling the rebate model that the entire drug-distribution complex is built on; how the Medicaid and ACA coverage cliff lands on insurers and hospitals on a 12-to-18-month delay; and how GLP-1s went from a rounding error to a fifth of some pharmacy budgets. The through-line is timing. Almost every credible voice this week was warning about a reckoning that hasn't shown up in the numbers yet, which is exactly when it's tradeable.

TL;DR

  • The IRA is a slow fuse, not a one-time haircut. As more drugs get price-controlled and list prices fall, the rebate spread that feeds PBMs, 340B hospitals, and plan premiums collapses with them, and the operators see it coming before the P&L does.
  • GLP-1s are now a structural cost line, not a fad. Medicare's GLP-1 "Bridge Program" launches July 1 at ~$50/month, and one actuary flagged these drugs already eating 20%+ of prescription spend at some coalitions.
  • Coverage losses are a 2027-2028 problem for managed care and hospitals. Medicaid work-reporting requirements and the ACA subsidy cliff are baked in; the revenue deterioration just hasn't crashed onto financial statements yet.

What's new

1. A "nuclear winter for biopharma" call on oncology economics. On the Vital Health Podcast (June 25), policy analyst Bill Smith, who has testified in multiple statehouses, argued that the stack of MFN, IRA and 340B is creating "perverse incentives" that disincentivize small-molecule oncology, citing a pre-ASCO preprint showing "a 35% reduction" in small-molecule oncology research. His sharpest read-through: "once you have 150 or 200 of the top selling drugs that are price controlled and the government is pushing down their list prices by 50% or more, the ability of hospitals to arbitrage the [340B] discounts is going to be enormously cut… hospitals are going to probably ask for a bailout." (Operator/insider, policy analyst.) Why it matters: this reframes the IRA as a hospital-finance and oncology-supply story, not just a pharma-margin story.

2. The IRA is cracking the rebate model from the inside. On Relentless Health Value (June 24), industry insider Stacey Richter explained that "lower list prices can collapse the rebate spread that is used to justify the game in the first place," pushing manufacturers toward cash-pay and direct-to-patient channels. She quoted a manufacturer executive directly: "I'd rather sell fewer prescriptions at a transparent, sustainable price that I can control than more prescriptions at a phantom list price where everyone gets paid, but me and patients get stuck with co-insurance on a number that isn't ever real." (Operator/insider, citing a manufacturer.) Why it matters: if even a handful of brands defect from formularies, the PBM rebate annuity starts to leak.

3. Medicare's GLP-1 Bridge Program goes live July 1, with a 2027 expiry. On NEJM Interviews (June 24), Vanderbilt health-policy professor Stacie Dusetzina detailed the new program that covers GLP-1s for weight loss outside Part D at roughly $50/month versus ~$350 cash. The broader "Balance" demonstration is on hold because Part D plan sponsors weren't interested in participating; Bridge now sunsets end of 2027 with "not currently a plan to launch the Balance model," and Dusetzina warned it "could have some upward pressure on the premiums in the Medicare Part B program." (Expert/academic, not an operator.)

4. GLP-1s are now a fifth of some drug budgets. On Actuary Voices (June 25), actuary Dr. Kimberly Ferrero said "some large pharmacy coalitions are reporting that a handful of GLP-1 receptor agonists account for over 20% of total prescription spending," while cautioning that long-term cost offsets "may take years or even decades to emerge." (Operator/insider, actuary.) Why it matters: the cost is immediate and visible; the savings are a hope. That asymmetry is the payer bear case.

5. The Medicaid redetermination wave is loaded. On Becker's Healthcare (June 20), Independence Health Group CEO Kelly Munson said she's "gravely concerned," noting it's "the procedural aspects… where people lose coverage, not because they actually should have." She pointed to Georgia and Arkansas work-requirement rollouts where "thousands of people drop off the rolls… who otherwise were eligible," feeding "uncompensated care costs" that hospitals then push back onto commercial rates. (Operator/insider, insurer CEO.)

The debate

Reform is overdue (bull case for patients/transparency). Mark Cuban, on CareTalk (June 26), made the populist case that PBMs "control… 85% of the formularies" and use formulary positioning as a club: brand makers net ~$300 on a $600 list drug after rebates but can't sell direct because PBMs threaten to "diminish [their] positioning." Transparency, on this view, is unambiguously good.

Reform is breaking things faster than it fixes them (bear case for innovation/providers). The Smith and Richter tape is the steel-man here: price controls plus 340B arbitrage plus rebate collapse are pushing capital away from elderly-skewed small-molecule oncology and toward asset classes that "avoid the elderly," while hospital and independent-oncology economics hollow out. Both sides are real, and the honest read is that they're not mutually exclusive: lower patient prices and chilled innovation can happen at the same time.

The names in play

The week's hard numbers came via Citeline's Scrip (June 22): Eli Lilly's Mounjaro hit $8.66B in Q1 2026 (more than doubling y/y), dethroning Merck's Keytruda as the world's top-selling drug; with Zepbound ($4.16B), the tirzepatide franchise cleared $12.8B in the quarter, and full-year sell-side consensus pegs Mounjaro at $33.1B and Zepbound at $19.3B (~$52B combined). Novo Nordisk moved the other way, Ozempic down $602M and Wegovy down $551M sequentially. BMY/Pfizer's Eliquis reached $4.14B (+16% y/y) but faces US loss of exclusivity in 2028. And AbbVie kept its M&A machine running with the ~$10.9B / $135.11-per-share Apogee Therapeutics deal to backfill its immunology franchise (Crain's Daily Gist, June 23). (Names data, journalist/pundit sourcing.)

Read-throughs

  • PBMs (CVS/Caremark, Cigna/Express Scripts, UNH/Optum): Beyond Cuban's formulary critique, the Pharmacy Podcast Network (June 26) flagged that CVS Health, Express Scripts and Optum are suing Tennessee over its "Fair Rx Act" pharmacy-ownership ban, mirroring Arkansas, after a state audit found PBMs reimbursing affiliated pharmacies "at significantly higher rates." Structural/legal risk to the vertically integrated model is building state by state.
  • Biosimilars/generics: Per Actuary Voices, semaglutide (Ozempic/Wegovy) is patent-protected "probably into 2031," and tirzepatide (Zepbound) until "about 2036," limiting near-term GLP-1 erosion but capping how fast payers get relief.
  • Ex-US: Scrip flagged a Brazilian bill seeking a compulsory license for Lilly's Mounjaro/Zepbound, a reminder that ex-US pricing pressure is a live tail risk for the franchise.
  • Medicaid/exchange insurers (CNC, MOH, ELV, UNH): The ACA subsidy cliff is real. One data-tracking analyst on Paging America (June 25) put 2025 effectuated enrollment near 22M and forecast 4-5M ACA disenrollees by year-end from subsidy expiration alone. Risk pools get sicker as the healthy drop off.
  • Hospitals (HCA, THC, UHS): On Achieving Health (June 24), revenue-cycle operators described "a delayed but meaningful deterioration risk emerging later in this decade," rising self-pay, higher denial rates, more bad debt as work requirements (Jan 2027) and provider-tax/state-directed-payment changes (FY2028) phase in. "The calm before we get choppy seas."

What changed

The GLP-1 Bridge Program crossed from proposal to a hard July 1 launch date this week, even as its parent "Balance" demonstration was shelved, a meaningful, if temporary, expansion of Medicare obesity-drug access. And the rebate model moved from "theoretically vulnerable" to "operators are already defecting": multiple manufacturers walking away from major PBM formularies and 340B/Medicaid entirely.